|Videos|December 24, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You
2
What Breast Cancer Survivors Should Know About Weight Loss and Long-Term Health
3
Diagnosed With Ovarian Cancer at 15: 10 Things That Helped Brynn Forlizzi Through Treatment
4
Lung Cancer Patient Shares How Community, Hope and Self-Advocacy Helped Her Through Treatment
5